- Stock Surge: Guardant Health’s stock jumped about 30% on Oct. 30, 2025, trading near $94 (from about $72 the day before) after its strong Q3 report and raised outlook.
- Q3 Beat: Q3 revenue was $265.2 million (up 39% year-on-year), far above the ~$235.7M consensus; non-GAAP EPS was –$0.39 vs –$0.79 expected.
- Raised Guidance: The company lifted 2025 revenue guidance to $965–970M (~31% growth). Q4 revenue is now seen around $935–970M (above the $922M consensus).
- Shield Screening Partnerships: Guardant is rapidly expanding access to its Shield™ blood-based colorectal cancer screening test via new deals with Quest Diagnostics, PathGroup, LabFlorida/SunDX and the American Cancer Society. These partnerships bring Shield to thousands of doctors, senior centers and hospitals nationwide.
- FDA & Product Wins: Guardant360™ – the company’s flagship liquid biopsy test – earned new FDA approvals (e.g. as a companion diagnostic for ESR1-mutated breast and lung cancer). Guardant also submitted its Guardant360 liquid biopsy for formal FDA review (PMA application).
- Analyst Upgrades: Wall Street is bullish. Firms like TD Cowen, Canaccord and BTIG have raised GH price targets (some to ~$100) after the Q3 beatinvesting.com. Piper Sandler and others note Guardant’s “first-mover advantage” in the hot liquid biopsy markettipranks.com.
Strong Q3 Earnings Propel Stock Higher
Guardant’s latest quarterly report blew past Wall Street’s expectations, sparking a sharp rally in its shares. For Q3 2025, revenue was $265.2 million, a 39% jump from a year ago and well above the ~$235 million analysts had forecast. On an adjusted basis, Guardant lost $0.39 per share, much better than the roughly $0.79 loss expected. Management immediately lifted the full-year sales outlook to $965–970 million (about 31% growth), up from $915–925M previously. As a result, GH stock jumped nearly 30% in morning trading on Oct. 30 (to about $94, from ~$72 at Thursday’s close). This breakout comes on top of an already huge run – shares were up over 210% year-over-year before the earnings release.
Guardant’s co-CEOs hailed the quarter’s breadth. Helmy Eltoukhy noted it was an “exceptional quarter” with “broad-based growth across our business,” including 40% year-over-year volume growth in cancer testinginvestors.guardanthealth.com. He pointed out that this strong momentum lifted Guardant past a $1 billion annualized revenue run-rate for the first time, underscoring the power of its liquid-biopsy and screening offerings. In short, real revenue growth (not one-time items) is accelerating, giving investors confidence in Guardant’s path.
Shield Test and Partnerships Expand Screening Access
Beyond raw numbers, much of Guardant’s recent news revolves around its Shield blood test for early cancer screening. Shield is the first FDA-approved blood test for routine colorectal cancer screening, meant as a more convenient alternative to colonoscopy or stool tests. In Q3 Guardant accelerated efforts to roll out Shield nationwide. For example, it announced a deal with Quest Diagnostics (Sept. 24) allowing doctors to order Shield through Quest’s massive lab networkinvestors.guardanthealth.com. Guardant’s co-CEO AmirAli Talasaz called this a “pivotal step in accelerating access” to the testinvestors.guardanthealth.com. In early September, Guardant also partnered with PathGroup, a large national lab service provider, to introduce Shield to 15,000 physicians and 250+ hospitals across 25 statesinvestors.guardanthealth.com.
Another strategic partnership with LabFlorida/SunDX Labs (Sept. 11) targets senior living communities. LabFlorida will offer Shield as a concierge service to seniors (a group that’s historically under-screened for colorectal cancer)investors.guardanthealth.cominvestors.guardanthealth.com. Talasaz said “Shield has the potential to be revolutionary for senior living,” making screening easy with a simple blood drawinvestors.guardanthealth.com. Guardant also teamed with the American Cancer Society (August 2025) to boost cancer-screening awareness in underserved communitiesinvestors.guardanthealth.com. In short, Guardant is rapidly scaling up distribution of Shield through multiple channels, which should drive future test volume and revenue.
The company is also improving the Shield test itself. In Q3, Guardant began rolling out Shield Version 2 with expanded capabilities. Notably, Guardant announced that Shield’s platform is being extended toward multi-cancer detection (MCD) – meaning the same blood test could eventually screen for other cancer types. Early data using Guardant’s InfinityAI analytics show promise for this MCD approachinvestors.guardanthealth.com. As AmirAli Talasaz put it, Guardant has “expanded Shield to include multi-cancer detection nationwide” in a new clinical data initiativeinvestors.guardanthealth.com. All of this amplifies the potential market for Shield well beyond colorectal cancer.
FDA Milestones and Product Pipeline
Guardant’s product pipeline beyond Shield also drew positive headlines. In October, the FDA approved Guardant360 CDx as a companion diagnostic for certain advanced breast and lung cancers. This means that doctors can use Guardant’s blood test to identify patients (e.g. with ESR1-mutated breast cancer for Lilly’s drug Inlyta) who qualify for specific targeted therapies. In another major step, Guardant submitted its Guardant360 liquid biopsy to the FDA for full PMA clearance – a key hurdle toward broader clinical adoption. (In parallel, Guardant’s Reveal™ test for monitoring immunotherapy response is under review by Medicare’s MolDx, which could unlock reimbursement.)
These milestones reinforce Guardant’s role in precision oncology. Investors are watching closely because regulatory approvals and insurance coverage could dramatically expand usage of Guardant’s tests. For example, analysts noted that Guardant360 test volume has now accelerated for five straight quarters, and Shield revenues ($24M in Q3) are running well ahead of expectations. Improved gross margins (about 300 basis points above forecasts) suggest Guardant is scaling efficiently. Management’s ability to push new tests through regulatory pathways (and partnerships) is a key factor fueling the stock’s recent rise.
Analysts Weigh In: Bullish Outlook
Wall Street analysts have responded bullishly to Guardant’s progress. TD Cowen’s David Westenberg raised his GH price target to $100 (from $72) immediately after the earningsinvesting.com. He noted that Guardant beat sales expectations by a wide margin and “momentum remains strong,” leaving “many upside levers” for the storyinvesting.com. Piper Sandler also lifted its target (to ~$90) and kept an Overweight rating, emphasizing Guardant’s “first-mover advantage” in liquid biopsytipranks.com. Other firms followed suit: Canaccord, BTIG and Wolfe Research each bumped their targets into the $90–$100 rangeinvesting.com. In short, analysts see room for more upside, forecasting further share gains if growth continues.
That optimism is reflected in GH’s consensus forecast: TipRanks data show the average 12-month analyst target was around $71 before the report (even though many were stuck in the 2024 view). After the quarter, top analysts have reset expectations much higher (some as high as $100). The Street’s message is clear: Guardant’s combination of strong growth, innovative products and partnerships merits a premium valuation.
Outlook
Guardant Health is in the spotlight right now, thanks to its blockbuster quarter and promising initiatives. In the near term, investors will watch the final Q4 results (due in early 2026) to see if revenue keeps beating forecasts. Longer term, key drivers will be continued adoption of Shield (especially as multi-cancer detection capabilities roll out), the commercial ramp of Guardant360 and Reveal, and any further FDA or reimbursement gains. Guardant still operates at a loss (as most biotech growth companies do), but improving margins and strong revenue gains give analysts confidence.
“The market sees Guardant as a leader in liquid biopsy and cancer screening,” notes Piper Sandler, which expects the market itself to grow even faster than broader genomic testingtipranks.com. If Guardant executes on its technology roadmap and partnerships, many analysts believe the stock can go higher from here.
Sources: Guardant Health Q3 earnings release and SEC filings; Reuters market data; Investing.com and TipRanks news reports; Guardant press releases on Shield partnerships; FDA approval announcement; analyst commentary noted above.
